239820

AMD3100 octahydrochloride hydrate

≥98% (HPLC), solid, CXCR4 antagonist, Calbiochem

• Synonyme(s) : CXCR4 Antagonist I, AMD3100, 1,1ʹ-(1,4-Phenylene bis(methylene))- bis-1,4,8,11-tetraazacyclotetradecane, 8HCl, JM3100, 1,1ʹ-(1,4-Phenylenebis(methylene))-bis-1,4,8,11-tetraazacyclotetradecane, 8HCl, JM3100
• Formule empirique (notation de Hill): C₂₈H₅₄N₈ · 8HCl
• Numéro CAS: 155148-31-5
• Poids moléculaire : 794.47
• Code UNSPSC : 51111800
• Nomenclature NACRES : NA.77

Propriétés

• product name: CXCR4 Antagonist I, AMD3100, The CXCR4 Antagonist I, AMD3100, also referenced under CAS 155148-31-5, controls the biological activity of CXCR4. This small molecule/inhibitor is primarily used for Cell Signaling applications.
• Niveau de qualité: 100
• Pureté: ≥98% (HPLC)
• Forme: solid
• Fabricant/nom de marque: Calbiochem^®
• Conditions de stockage: OK to freeze; desiccated (hygroscopic); protect from light
• Couleur: off-white
• Solubilité: water: 10 mg/mL
• Conditions d'expédition: ambient
• Température de stockage: 2-8°C
• InChI: 1S/C28H54N8.8ClH/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H
• Clé InChI: UEUPDYPUTTUXLJ-UHFFFAOYSA-N

Description

Description générale

A symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4 (IC₅₀ = 108 and 245 nM using rat and human CXCR4, respectively) and inhibits SDF1-induced Ca²⁺ flux (by 100% at 100 ng/ml in SUP-T1 and THP-1 cultures) as well as CXCR4-, but not CCR5-, mediated HIV infection (IC₅₀ ≤200 nM), while enhancing the binding of SDF1 to CXCR7 (by ~60% at 1 mM with CXCR7-expressing HEK293T cells) and SDF1-induced β-arrestin recruitment to CXCR7 (EC₅₀ = 6.48 and 11.8 nM, in the presence and absence of 10 µM AMD3100, respectively). Administration AMD3100 via intravenous infusion is also reported to result in hematopoietic stem cell mobilization in humans, dogs, and mice in vivo. Exhibits no inhibitory effects against chemokine-induced signaling via CXCR1/2/3 or CCR1/2/3/4/5/6/7/8/9.

A symmetrical bicyclam compound that antagonizes CXCL12 (SDF1) binding to CXCR4 (IC₅₀ = 108 and 245 nM using rat and human CXCR4, respectively) and inhibits SDF1-induced Ca²⁺ flux (by 100% at 100 ng/ml in SUP-T1 and THP-1 cultures) as well as CXCR4-, but not CCR5-, mediated HIV infection (IC₅₀ ≤200 nM), while enhancing the binding of SDF1 to CXCR7 (by ~60% at 1 mM with CXCR7-expressing HEK293T cells) and SDF1-induced β-arrestin recruitment to CXCR7 (EC₅₀ = 6.48 and 11.8 nM, in the presence and absence of 10 µM AMD3100, respectively). Administration AMD3100 via intravenous infusion is also reported to result in hematopoietic stem cell mobilization in humans, dogs, and mice in vivo. Exhibits no inhibitory effects against chemokine-induced signaling via CXCR1/2/3 or CCR1/2/3/4/5/6/7/8/9. Also available as a 50 mM solution in H₂O (Cat. No. 239825).

Conditionnement

Packaged under inert gas

Avertissement

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Autres remarques

Kalatskaya, I., et al. 2009. Mol. Pharmacol.77, 1240.
Pitchford, S.C., et al. 2009. Cell Stem Cell4, 62.
De Clercq, E. 2009. Biochem. Pharmacol. , 1655.
Thoma, G., et al. 2008. J. Med. Chem.51, 7915.
De Clercq, E. 2000. Mol. Pharmacol.57, 833.

Informations légales

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable